In the last decade, regarding CSC subpopulations in primary human BC, ESA+/CD44+/CD24−/low phenotype has been used extensively to identify and isolate BC stem cells (BCSCs) with increased tumorigenicity (Ablett et al., 2012). This evidence concerns the gene CD44 and breast cancer.